

Reference number(s)
2563-H

SPECIALTY QUANTITY LIMIT PROGRAM

CRYSVITA (burosumab-twza)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of X-linked hypophosphatemia fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Crysvita 10mg vial	1 vial per 14 days	Pediatric: 0.8 mg/kg of body weight, rounded to the nearest 10 mg administered every 2 weeks. The minimum starting dose is 10 mg up to a maximum dose of 90 mg. Adult: 1 mg/kg of body weight, rounded to the nearest 10 mg administered every 4 weeks. The minimum starting dose is 10 mg up to a maximum dose of 90 mg.
Crysvita 20mg vial	4 vials per 14 days	
Crysvita 30mg vial	3 vials per 14 days	

III. REFERENCES

1. Crysvita [package insert]. Novato, CA: Ultragenyx Pharmaceutical; April 2018